Caitong International Asset Management’s Telomir Pharmaceuticals TELO Stock Holding History

Caitong International Asset Management’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3	Buy	+2	New	+$3	﹤0.01%	2399

Other funds holding TELO

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WIA

World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Caitong International Asset Management's TELO Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Telomir Pharmaceuticals (TELO) in Q1 2026: 2 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #2399 among its holdings.

27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

Caitong International Asset Management held 2 shares of Telomir Pharmaceuticals worth $3 as of Q1 2026.
Telomir Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
Telomir Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2399 holding.
27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.